Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 373Neoplasms 323Neoplasm Metastasis 286Leukemia, Myeloid, Acute 277Breast Neoplasms 271Colorectal Neoplasms 238Melanoma 193Ovarian Neoplasms 191Recurrence 183Multiple Myeloma 178Prostatic Neoplasms 156Lung Neoplasms 156Pancreatic Neoplasms 152Squamous Cell Carcinoma of Head and Neck 150Lymphoma, Non-Hodgkin 146Glioblastoma 145Triple Negative Breast Neoplasms 119Myelodysplastic Syndromes 114Carcinoma, Renal Cell 111Stomach Neoplasms 110Glioma 108Brain Neoplasms 105Advanced Solid Tumors 104Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Lymphoma, Large B-Cell, Diffuse 101Lymphoma 100Lymphoma, B-Cell 97Carcinoma, Hepatocellular 95Endometrial Neoplasms 92Lymphoma, Follicular 91

Interventions

ivosidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × IDH1 Mutation Myeloid Neoplasms × 1 year × Clear all
NCT03564821 2025-11-04

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Massachusetts General Hospital

Phase 1 Completed
18 enrolled
Myeloid

IDH1 Mutation Myeloid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡